#FORMAT=WebAnno TSV 3.2
#T_SP=webanno.custom.Referent|entity|infstat
#T_RL=webanno.custom.Coref|type|BT_webanno.custom.Referent


#Text=4. Discussion
1-1	0-2	4.	_	_	_	_
1-2	3-13	Discussion	abstract	new	_	_

#Text=iSGLT2s are a new class of oral hypoglycaemic drugs that block glucose reabsorption at the renal level , thus promoting urine glucose and sodium excretion and reducing plasma glucose levels .
2-1	14-21	iSGLT2s	abstract	new	coref	2-3[3_0]
2-2	22-25	are	_	_	_	_
2-3	26-27	a	abstract[3]	giv[3]	coref	6-6[0_3]
2-4	28-31	new	abstract[3]	giv[3]	_	_
2-5	32-37	class	abstract[3]	giv[3]	_	_
2-6	38-40	of	abstract[3]	giv[3]	_	_
2-7	41-45	oral	abstract[3]|substance[4]	giv[3]|new[4]	coref	8-15[69_4]
2-8	46-59	hypoglycaemic	abstract[3]|substance[4]	giv[3]|new[4]	_	_
2-9	60-65	drugs	abstract[3]|substance[4]	giv[3]|new[4]	_	_
2-10	66-70	that	_	_	_	_
2-11	71-76	block	_	_	_	_
2-12	77-84	glucose	substance|event[6]	new|new[6]	coref|coref	2-21[10_0]|2-21[10_0]
2-13	85-97	reabsorption	event[6]	new[6]	_	_
2-14	98-100	at	_	_	_	_
2-15	101-104	the	abstract[8]	new[8]	_	_
2-16	105-110	renal	abstract|abstract[8]	new|new[8]	_	_
2-17	111-116	level	abstract[8]	new[8]	_	_
2-18	117-118	,	_	_	_	_
2-19	119-123	thus	_	_	_	_
2-20	124-133	promoting	_	_	_	_
2-21	134-139	urine	substance|substance[10]|abstract[11]	new|giv[10]|new[11]	coref|coref|coref|coref|coref|coref	2-29[0_10]|4-17[34_11]|2-29[0_10]|4-17[34_11]|2-29[0_10]|4-17[34_11]
2-22	140-147	glucose	substance[10]|abstract[11]	giv[10]|new[11]	_	_
2-23	148-151	and	abstract[11]	new[11]	_	_
2-24	152-158	sodium	abstract[11]|substance|abstract[13]	new[11]|new|new[13]	_	_
2-25	159-168	excretion	abstract[11]|abstract[13]	new[11]|new[13]	_	_
2-26	169-172	and	_	_	_	_
2-27	173-181	reducing	_	_	_	_
2-28	182-188	plasma	abstract|abstract[16]	new|new[16]	coref|coref|coref|coref	4-18|4-21[36_16]|4-18|4-21[36_16]
2-29	189-196	glucose	substance|abstract[16]	giv|new[16]	coref	4-17[33_0]
2-30	197-203	levels	abstract[16]	new[16]	_	_
2-31	204-205	.	_	_	_	_

#Text=In the present study , we have focused on the effects of empagliflozin on oxidative stress in the leukocytes of T2D subjects , and on inflammatory parameters .
3-1	206-208	In	_	_	_	_
3-2	209-212	the	event[17]	new[17]	coref	9-11[75_17]
3-3	213-220	present	event[17]	new[17]	_	_
3-4	221-226	study	event[17]	new[17]	_	_
3-5	227-228	,	_	_	_	_
3-6	229-231	we	person	acc	ana	4-24
3-7	232-236	have	_	_	_	_
3-8	237-244	focused	_	_	_	_
3-9	245-247	on	_	_	_	_
3-10	248-251	the	abstract[19]	new[19]	coref	11-16[97_19]
3-11	252-259	effects	abstract[19]	new[19]	_	_
3-12	260-262	of	abstract[19]	new[19]	_	_
3-13	263-276	empagliflozin	abstract[19]|substance	new[19]|new	coref	4-38[45_0]
3-14	277-279	on	abstract[19]	new[19]	_	_
3-15	280-289	oxidative	abstract[19]|abstract|abstract[22]	new[19]|new|new[22]	coref|coref|coref|coref	14-26[134_22]|18-16|14-26[134_22]|18-16
3-16	290-296	stress	abstract[19]|abstract[22]	new[19]|new[22]	_	_
3-17	297-299	in	abstract[19]|abstract[22]	new[19]|new[22]	_	_
3-18	300-303	the	abstract[19]|abstract[22]|person[23]	new[19]|new[22]|new[23]	_	_
3-19	304-314	leukocytes	abstract[19]|abstract[22]|person[23]	new[19]|new[22]|new[23]	_	_
3-20	315-317	of	abstract[19]|abstract[22]|person[23]	new[19]|new[22]|new[23]	_	_
3-21	318-321	T2D	abstract[19]|abstract[22]|person[23]|abstract|abstract[25]	new[19]|new[22]|new[23]|new|new[25]	coref|coref	13-17|13-17
3-22	322-330	subjects	abstract[19]|abstract[22]|person[23]|abstract[25]	new[19]|new[22]|new[23]|new[25]	_	_
3-23	331-332	,	_	_	_	_
3-24	333-336	and	_	_	_	_
3-25	337-339	on	_	_	_	_
3-26	340-352	inflammatory	abstract[26]	new[26]	coref	5-7[49_26]
3-27	353-363	parameters	abstract[26]	new[26]	_	_
3-28	364-365	.	_	_	_	_

#Text=In addition to a reduction in body weight and an improved metabolic profile — characterized by reduced plasma glucose and HbA1c levels — we observed a reduction in mitochondrial superoxide production in diabetic patients after treatment with the iSGLT2 empagliflozin , together with increased antioxidant defenses .
4-1	366-368	In	_	_	_	_
4-2	369-377	addition	_	_	_	_
4-3	378-380	to	_	_	_	_
4-4	381-382	a	abstract[27]	new[27]	coref	4-26[38_27]
4-5	383-392	reduction	abstract[27]	new[27]	_	_
4-6	393-395	in	abstract[27]	new[27]	_	_
4-7	396-400	body	abstract[27]|object|abstract[29]	new[27]|new|new[29]	coref|coref|coref|coref	11-22|11-22[100_29]|11-22|11-22[100_29]
4-8	401-407	weight	abstract[27]|abstract[29]	new[27]|new[29]	_	_
4-9	408-411	and	abstract[27]	new[27]	_	_
4-10	412-414	an	abstract[27]|abstract[31]	new[27]|new[31]	coref	6-10[58_31]
4-11	415-423	improved	abstract[27]|abstract[31]	new[27]|new[31]	_	_
4-12	424-433	metabolic	abstract[27]|person|abstract[31]	new[27]|new|new[31]	_	_
4-13	434-441	profile	abstract[27]|abstract[31]	new[27]|new[31]	_	_
4-14	442-443	—	_	_	_	_
4-15	444-457	characterized	_	_	_	_
4-16	458-460	by	_	_	_	_
4-17	461-468	reduced	substance[33]|abstract[34]	giv[33]|giv[34]	_	_
4-18	469-475	plasma	abstract|substance[33]|abstract[34]	giv|giv[33]|giv[34]	coref	21-6
4-19	476-483	glucose	substance[33]|abstract[34]	giv[33]|giv[34]	_	_
4-20	484-487	and	abstract[34]	giv[34]	_	_
4-21	488-493	HbA1c	abstract[34]|abstract|abstract[36]	giv[34]|new|giv[36]	coref|coref	10-7|10-7
4-22	494-500	levels	abstract[34]|abstract[36]	giv[34]|giv[36]	_	_
4-23	501-502	—	_	_	_	_
4-24	503-505	we	person	giv	ana	7-19
4-25	506-514	observed	_	_	_	_
4-26	515-516	a	abstract[38]	giv[38]	coref	9-17[76_38]
4-27	517-526	reduction	abstract[38]	giv[38]	_	_
4-28	527-529	in	abstract[38]	giv[38]	_	_
4-29	530-543	mitochondrial	abstract[38]|object|abstract[41]	giv[38]|new|new[41]	coref|coref|coref|coref	16-5[150_41]|19-14|16-5[150_41]|19-14
4-30	544-554	superoxide	abstract[38]|substance|abstract[41]	giv[38]|new|new[41]	coref	19-15
4-31	555-565	production	abstract[38]|abstract[41]	giv[38]|new[41]	_	_
4-32	566-568	in	abstract[38]|abstract[41]	giv[38]|new[41]	_	_
4-33	569-577	diabetic	abstract[38]|abstract[41]|person[42]	giv[38]|new[41]|new[42]	coref	13-17[122_42]
4-34	578-586	patients	abstract[38]|abstract[41]|person[42]	giv[38]|new[41]|new[42]	_	_
4-35	587-592	after	abstract[38]	giv[38]	_	_
4-36	593-602	treatment	abstract[38]|abstract[43]	giv[38]|new[43]	coref	5-16[51_43]
4-37	603-607	with	abstract[38]|abstract[43]	giv[38]|new[43]	_	_
4-38	608-611	the	abstract[38]|abstract[43]|substance[45]	giv[38]|new[43]|giv[45]	coref	5-18[0_45]
4-39	612-618	iSGLT2	abstract[38]|abstract[43]|object|substance[45]	giv[38]|new[43]|new|giv[45]	coref	11-11
4-40	619-632	empagliflozin	abstract[38]|abstract[43]|substance[45]	giv[38]|new[43]|giv[45]	_	_
4-41	633-634	,	abstract[38]|abstract[43]	giv[38]|new[43]	_	_
4-42	635-643	together	abstract[38]|abstract[43]|abstract[47]	giv[38]|new[43]|new[47]	coref	15-5[138_47]
4-43	644-648	with	abstract[38]|abstract[43]|abstract[47]	giv[38]|new[43]|new[47]	_	_
4-44	649-658	increased	abstract[38]|abstract[43]|abstract[47]	giv[38]|new[43]|new[47]	_	_
4-45	659-670	antioxidant	abstract[38]|abstract[43]|abstract|abstract[47]	giv[38]|new[43]|new|new[47]	coref	15-6
4-46	671-679	defenses	abstract[38]|abstract[43]|abstract[47]	giv[38]|new[43]|new[47]	_	_
4-47	680-681	.	_	_	_	_

#Text=Moreover , reduced proinflammatory markers and increased anti-inflammatory parameters were maintained after 24 weeks of treatment with empagliflozin .
5-1	682-690	Moreover	_	_	_	_
5-2	691-692	,	_	_	_	_
5-3	693-700	reduced	abstract[48]	new[48]	_	_
5-4	701-716	proinflammatory	abstract[48]	new[48]	_	_
5-5	717-724	markers	abstract[48]	new[48]	_	_
5-6	725-728	and	_	_	_	_
5-7	729-738	increased	abstract[49]	giv[49]	ana	6-2[0_49]
5-8	739-756	anti-inflammatory	abstract[49]	giv[49]	_	_
5-9	757-767	parameters	abstract[49]	giv[49]	_	_
5-10	768-772	were	_	_	_	_
5-11	773-783	maintained	_	_	_	_
5-12	784-789	after	_	_	_	_
5-13	790-792	24	time[50]	new[50]	_	_
5-14	793-798	weeks	time[50]	new[50]	_	_
5-15	799-801	of	time[50]	new[50]	_	_
5-16	802-811	treatment	time[50]|abstract[51]	new[50]|giv[51]	coref	7-1[60_51]
5-17	812-816	with	time[50]|abstract[51]	new[50]|giv[51]	_	_
5-18	817-830	empagliflozin	time[50]|abstract[51]|substance	new[50]|giv[51]|giv	coref	7-1
5-19	831-832	.	_	_	_	_

#Text=Besides their glucose-lowering effect , iSGLT2s produce changes in the lipid profile that should also be highlighted .
6-1	833-840	Besides	_	_	_	_
6-2	841-846	their	abstract|abstract[54]	giv|new[54]	coref|coref	18-11[175_54]|18-11[175_54]
6-3	847-863	glucose-lowering	abstract[54]	new[54]	_	_
6-4	864-870	effect	abstract[54]	new[54]	_	_
6-5	871-872	,	_	_	_	_
6-6	873-880	iSGLT2s	abstract	giv	coref	8-11
6-7	881-888	produce	_	_	_	_
6-8	889-896	changes	abstract	new	coref	21-3[202_0]
6-9	897-899	in	_	_	_	_
6-10	900-903	the	abstract[58]	giv[58]	_	_
6-11	904-909	lipid	abstract|abstract[58]	new|giv[58]	_	_
6-12	910-917	profile	abstract[58]	giv[58]	_	_
6-13	918-922	that	_	_	_	_
6-14	923-929	should	_	_	_	_
6-15	930-934	also	_	_	_	_
6-16	935-937	be	_	_	_	_
6-17	938-949	highlighted	_	_	_	_
6-18	950-951	.	_	_	_	_

#Text=Empagliflozin treatment is correlated with increased total cholesterol due to slight increases in HDL-c and LDL-c , as we have observed , and reported in other studies .
7-1	952-965	Empagliflozin	substance|abstract[60]	giv|giv[60]	coref|coref|coref|coref	9-28[80_0]|11-9[0_60]|9-28[80_0]|11-9[0_60]
7-2	966-975	treatment	abstract[60]	giv[60]	_	_
7-3	976-978	is	_	_	_	_
7-4	979-989	correlated	_	_	_	_
7-5	990-994	with	_	_	_	_
7-6	995-1004	increased	substance[61]	new[61]	_	_
7-7	1005-1010	total	substance[61]	new[61]	_	_
7-8	1011-1022	cholesterol	substance[61]	new[61]	_	_
7-9	1023-1026	due	_	_	_	_
7-10	1027-1029	to	_	_	_	_
7-11	1030-1036	slight	abstract[62]	new[62]	_	_
7-12	1037-1046	increases	abstract[62]	new[62]	_	_
7-13	1047-1049	in	abstract[62]	new[62]	_	_
7-14	1050-1055	HDL-c	abstract[62]|quantity	new[62]|new	_	_
7-15	1056-1059	and	abstract[62]	new[62]	_	_
7-16	1060-1065	LDL-c	abstract[62]|abstract	new[62]|new	_	_
7-17	1066-1067	,	_	_	_	_
7-18	1068-1070	as	_	_	_	_
7-19	1071-1073	we	person	giv	ana	19-1
7-20	1074-1078	have	_	_	_	_
7-21	1079-1087	observed	_	_	_	_
7-22	1088-1089	,	_	_	_	_
7-23	1090-1093	and	_	_	_	_
7-24	1094-1102	reported	_	_	_	_
7-25	1103-1105	in	_	_	_	_
7-26	1106-1111	other	abstract[66]	new[66]	coref	9-6[72_66]
7-27	1112-1119	studies	abstract[66]	new[66]	_	_
7-28	1120-1121	.	_	_	_	_

#Text=However , there is a well-documented cardiovascular protection exerted by iSGLT2s , which endows these drugs with clinical potential .
8-1	1122-1129	However	_	_	_	_
8-2	1130-1131	,	_	_	_	_
8-3	1132-1137	there	_	_	_	_
8-4	1138-1140	is	_	_	_	_
8-5	1141-1142	a	abstract[67]	new[67]	coref	10-34[91_67]
8-6	1143-1158	well-documented	abstract[67]	new[67]	_	_
8-7	1159-1173	cardiovascular	abstract[67]	new[67]	_	_
8-8	1174-1184	protection	abstract[67]	new[67]	_	_
8-9	1185-1192	exerted	_	_	_	_
8-10	1193-1195	by	_	_	_	_
8-11	1196-1203	iSGLT2s	object	giv	_	_
8-12	1204-1205	,	_	_	_	_
8-13	1206-1211	which	_	_	_	_
8-14	1212-1218	endows	_	_	_	_
8-15	1219-1224	these	substance[69]	giv[69]	_	_
8-16	1225-1230	drugs	substance[69]	giv[69]	_	_
8-17	1231-1235	with	_	_	_	_
8-18	1236-1244	clinical	abstract[70]	new[70]	ana	9-1[0_70]
8-19	1245-1254	potential	abstract[70]	new[70]	_	_
8-20	1255-1256	.	_	_	_	_

#Text=This has been reflected by several studies , such as the EMPA-REG OUTCOME study in which a reduction of 38 % in cardiovascular mortality was evident in the empagliflozin vs. placebo group .
9-1	1257-1261	This	abstract	giv	_	_
9-2	1262-1265	has	_	_	_	_
9-3	1266-1270	been	_	_	_	_
9-4	1271-1280	reflected	_	_	_	_
9-5	1281-1283	by	_	_	_	_
9-6	1284-1291	several	abstract[72]	giv[72]	coref	17-21[171_72]
9-7	1292-1299	studies	abstract[72]	giv[72]	_	_
9-8	1300-1301	,	abstract[72]	giv[72]	_	_
9-9	1302-1306	such	abstract[72]	giv[72]	_	_
9-10	1307-1309	as	abstract[72]	giv[72]	_	_
9-11	1310-1313	the	abstract[72]|event[75]	giv[72]|giv[75]	coref	10-10[85_75]
9-12	1314-1322	EMPA-REG	abstract[72]|organization|event[75]	giv[72]|new|giv[75]	coref	12-21
9-13	1323-1330	OUTCOME	abstract[72]|abstract|event[75]	giv[72]|new|giv[75]	coref	12-22
9-14	1331-1336	study	abstract[72]|event[75]	giv[72]|giv[75]	_	_
9-15	1337-1339	in	_	_	_	_
9-16	1340-1345	which	_	_	_	_
9-17	1346-1347	a	abstract[76]	giv[76]	coref	10-4[83_76]
9-18	1348-1357	reduction	abstract[76]	giv[76]	_	_
9-19	1358-1360	of	abstract[76]	giv[76]	_	_
9-20	1361-1363	38	abstract[76]|quantity[77]	giv[76]|new[77]	_	_
9-21	1364-1365	%	abstract[76]|quantity[77]	giv[76]|new[77]	_	_
9-22	1366-1368	in	abstract[76]|quantity[77]	giv[76]|new[77]	_	_
9-23	1369-1383	cardiovascular	abstract[76]|quantity[77]|abstract|event[79]	giv[76]|new[77]|new|new[79]	coref|coref|coref|coref	10-38|10-38[93_79]|10-38|10-38[93_79]
9-24	1384-1393	mortality	abstract[76]|quantity[77]|event[79]	giv[76]|new[77]|new[79]	_	_
9-25	1394-1397	was	_	_	_	_
9-26	1398-1405	evident	_	_	_	_
9-27	1406-1408	in	_	_	_	_
9-28	1409-1412	the	substance[80]	giv[80]	coref	12-18[111_80]
9-29	1413-1426	empagliflozin	substance[80]	giv[80]	_	_
9-30	1427-1430	vs.	substance[80]	giv[80]	_	_
9-31	1431-1438	placebo	substance[80]|person|abstract[82]	giv[80]|new|new[82]	_	_
9-32	1439-1444	group	substance[80]|abstract[82]	giv[80]|new[82]	_	_
9-33	1445-1446	.	_	_	_	_

#Text=However , neither the reduction in HbA1c observed in the study ( 0.60 % over 12 weeks ) nor the reduction in SBP ( up to 5 mmHg ) are sufficient to explain the reported protection against cardiovascular mortality .
10-1	1447-1454	However	_	_	_	_
10-2	1455-1456	,	_	_	_	_
10-3	1457-1464	neither	_	_	_	_
10-4	1465-1468	the	abstract[83]	giv[83]	coref	10-20[88_83]
10-5	1469-1478	reduction	abstract[83]	giv[83]	_	_
10-6	1479-1481	in	abstract[83]	giv[83]	_	_
10-7	1482-1487	HbA1c	abstract[83]|substance	giv[83]|giv	coref	11-20
10-8	1488-1496	observed	_	_	_	_
10-9	1497-1499	in	_	_	_	_
10-10	1500-1503	the	event[85]	giv[85]	coref	12-20[114_85]
10-11	1504-1509	study	event[85]	giv[85]	_	_
10-12	1510-1511	(	_	_	_	_
10-13	1512-1516	0.60	quantity[86]	new[86]	_	_
10-14	1517-1518	%	quantity[86]	new[86]	_	_
10-15	1519-1523	over	time[87]	new[87]	_	_
10-16	1524-1526	12	time[87]	new[87]	_	_
10-17	1527-1532	weeks	time[87]	new[87]	_	_
10-18	1533-1534	)	_	_	_	_
10-19	1535-1538	nor	_	_	_	_
10-20	1539-1542	the	abstract[88]	giv[88]	coref	12-5[105_88]
10-21	1543-1552	reduction	abstract[88]	giv[88]	_	_
10-22	1553-1555	in	abstract[88]	giv[88]	_	_
10-23	1556-1559	SBP	abstract[88]|substance	giv[88]|new	_	_
10-24	1560-1561	(	abstract[88]	giv[88]	_	_
10-25	1562-1564	up	abstract[88]	giv[88]	_	_
10-26	1565-1567	to	abstract[88]	giv[88]	_	_
10-27	1568-1569	5	abstract[88]|quantity[90]	giv[88]|new[90]	ana	11-16[0_90]
10-28	1570-1574	mmHg	abstract[88]|quantity[90]	giv[88]|new[90]	_	_
10-29	1575-1576	)	abstract[88]	giv[88]	_	_
10-30	1577-1580	are	_	_	_	_
10-31	1581-1591	sufficient	_	_	_	_
10-32	1592-1594	to	_	_	_	_
10-33	1595-1602	explain	_	_	_	_
10-34	1603-1606	the	abstract[91]	giv[91]	coref	14-12[130_91]
10-35	1607-1615	reported	abstract[91]	giv[91]	_	_
10-36	1616-1626	protection	abstract[91]	giv[91]	_	_
10-37	1627-1634	against	abstract[91]	giv[91]	_	_
10-38	1635-1649	cardiovascular	abstract[91]|abstract|abstract[93]	giv[91]|giv|giv[93]	coref|coref	11-34|11-34
10-39	1650-1659	mortality	abstract[91]|abstract[93]	giv[91]|giv[93]	_	_
10-40	1660-1661	.	_	_	_	_

#Text=Interestingly , as little as 24 weeks of treatment with iSGLT2 is sufficient to witness their beneficial effects on HbA1c , body weight , blood pressure and , most importantly , on the cardiovascular system .
11-1	1662-1675	Interestingly	_	_	_	_
11-2	1676-1677	,	_	_	_	_
11-3	1678-1680	as	_	_	_	_
11-4	1681-1687	little	_	_	_	_
11-5	1688-1690	as	_	_	_	_
11-6	1691-1693	24	_	_	_	_
11-7	1694-1699	weeks	_	_	_	_
11-8	1700-1702	of	_	_	_	_
11-9	1703-1712	treatment	abstract	giv	coref	13-13
11-10	1713-1717	with	_	_	_	_
11-11	1718-1724	iSGLT2	abstract	giv	coref	14-17
11-12	1725-1727	is	_	_	_	_
11-13	1728-1738	sufficient	_	_	_	_
11-14	1739-1741	to	_	_	_	_
11-15	1742-1749	witness	_	_	_	_
11-16	1750-1755	their	quantity|abstract[97]	giv|giv[97]	_	_
11-17	1756-1766	beneficial	abstract[97]	giv[97]	_	_
11-18	1767-1774	effects	abstract[97]	giv[97]	_	_
11-19	1775-1777	on	abstract[97]	giv[97]	_	_
11-20	1778-1783	HbA1c	abstract[97]|substance	giv[97]|giv	_	_
11-21	1784-1785	,	abstract[97]	giv[97]	_	_
11-22	1786-1790	body	abstract[97]|object|object[100]	giv[97]|giv|giv[100]	_	_
11-23	1791-1797	weight	abstract[97]|object[100]	giv[97]|giv[100]	_	_
11-24	1798-1799	,	abstract[97]	giv[97]	_	_
11-25	1800-1805	blood	abstract[97]|abstract[101]	giv[97]|new[101]	_	_
11-26	1806-1814	pressure	abstract[97]|abstract[101]	giv[97]|new[101]	_	_
11-27	1815-1818	and	_	_	_	_
11-28	1819-1820	,	_	_	_	_
11-29	1821-1825	most	abstract[103]	new[103]	coref	16-11[154_103]
11-30	1826-1837	importantly	abstract[103]	new[103]	_	_
11-31	1838-1839	,	abstract[103]	new[103]	_	_
11-32	1840-1842	on	abstract[103]	new[103]	_	_
11-33	1843-1846	the	abstract[103]	new[103]	_	_
11-34	1847-1861	cardiovascular	abstract|abstract[103]	giv|new[103]	coref	14-13
11-35	1862-1868	system	abstract[103]	new[103]	_	_
11-36	1869-1870	.	_	_	_	_

#Text=As an example , the reduction in hospitalization rates for heart failure in the group treated with empagliflozin in the EMPA-REG OUTCOME study was already significant at this time point .
12-1	1871-1873	As	_	_	_	_
12-2	1874-1876	an	abstract[104]	new[104]	_	_
12-3	1877-1884	example	abstract[104]	new[104]	_	_
12-4	1885-1886	,	_	_	_	_
12-5	1887-1890	the	abstract[105]	giv[105]	_	_
12-6	1891-1900	reduction	abstract[105]	giv[105]	_	_
12-7	1901-1903	in	abstract[105]	giv[105]	_	_
12-8	1904-1919	hospitalization	abstract[105]|abstract|abstract[107]	giv[105]|new|new[107]	_	_
12-9	1920-1925	rates	abstract[105]|abstract[107]	giv[105]|new[107]	_	_
12-10	1926-1929	for	abstract[105]|abstract[107]	giv[105]|new[107]	_	_
12-11	1930-1935	heart	abstract[105]|abstract[107]|object|event[109]	giv[105]|new[107]|new|new[109]	_	_
12-12	1936-1943	failure	abstract[105]|abstract[107]|event[109]	giv[105]|new[107]|new[109]	_	_
12-13	1944-1946	in	abstract[105]|abstract[107]|event[109]	giv[105]|new[107]|new[109]	_	_
12-14	1947-1950	the	abstract[105]|abstract[107]|event[109]|person[110]	giv[105]|new[107]|new[109]|new[110]	_	_
12-15	1951-1956	group	abstract[105]|abstract[107]|event[109]|person[110]	giv[105]|new[107]|new[109]|new[110]	_	_
12-16	1957-1964	treated	_	_	_	_
12-17	1965-1969	with	_	_	_	_
12-18	1970-1983	empagliflozin	substance[111]	giv[111]	coref	13-15[120_111]
12-19	1984-1986	in	substance[111]	giv[111]	_	_
12-20	1987-1990	the	substance[111]|event[114]	giv[111]|giv[114]	coref	13-1[116_114]
12-21	1991-1999	EMPA-REG	substance[111]|organization|event[114]	giv[111]|giv|giv[114]	_	_
12-22	2000-2007	OUTCOME	substance[111]|abstract|event[114]	giv[111]|giv|giv[114]	_	_
12-23	2008-2013	study	substance[111]|event[114]	giv[111]|giv[114]	_	_
12-24	2014-2017	was	_	_	_	_
12-25	2018-2025	already	_	_	_	_
12-26	2026-2037	significant	_	_	_	_
12-27	2038-2040	at	_	_	_	_
12-28	2041-2045	this	time[115]	new[115]	_	_
12-29	2046-2050	time	time[115]	new[115]	_	_
12-30	2051-2056	point	time[115]	new[115]	_	_
12-31	2057-2058	.	_	_	_	_

#Text=A recent study demonstrated an improved arterial stiffness after 6 weeks of treatment with empagliflozin in T2D patients , and hs-CRP was shown to be one of the main significant determinants for this improvement .
13-1	2059-2060	A	event[116]	giv[116]	_	_
13-2	2061-2067	recent	event[116]	giv[116]	_	_
13-3	2068-2073	study	event[116]	giv[116]	_	_
13-4	2074-2086	demonstrated	_	_	_	_
13-5	2087-2089	an	abstract[117]	new[117]	_	_
13-6	2090-2098	improved	abstract[117]	new[117]	_	_
13-7	2099-2107	arterial	abstract[117]	new[117]	_	_
13-8	2108-2117	stiffness	abstract[117]	new[117]	_	_
13-9	2118-2123	after	abstract[117]	new[117]	_	_
13-10	2124-2125	6	abstract[117]|time[118]	new[117]|new[118]	_	_
13-11	2126-2131	weeks	abstract[117]|time[118]	new[117]|new[118]	_	_
13-12	2132-2134	of	abstract[117]|time[118]	new[117]|new[118]	_	_
13-13	2135-2144	treatment	abstract[117]|time[118]|abstract	new[117]|new[118]|giv	coref	14-17[132_0]
13-14	2145-2149	with	abstract[117]|time[118]	new[117]|new[118]	_	_
13-15	2150-2163	empagliflozin	abstract[117]|time[118]|substance[120]	new[117]|new[118]|giv[120]	coref	21-13[0_120]
13-16	2164-2166	in	abstract[117]|time[118]|substance[120]	new[117]|new[118]|giv[120]	_	_
13-17	2167-2170	T2D	abstract[117]|time[118]|substance[120]|abstract|person[122]	new[117]|new[118]|giv[120]|giv|giv[122]	coref|coref|coref|coref	15-30|19-5[184_122]|15-30|19-5[184_122]
13-18	2171-2179	patients	abstract[117]|time[118]|substance[120]|person[122]	new[117]|new[118]|giv[120]|giv[122]	_	_
13-19	2180-2181	,	_	_	_	_
13-20	2182-2185	and	_	_	_	_
13-21	2186-2192	hs-CRP	abstract	new	_	_
13-22	2193-2196	was	_	_	_	_
13-23	2197-2202	shown	_	_	_	_
13-24	2203-2205	to	_	_	_	_
13-25	2206-2208	be	_	_	_	_
13-26	2209-2212	one	abstract[124]	new[124]	_	_
13-27	2213-2215	of	abstract[124]	new[124]	_	_
13-28	2216-2219	the	abstract[124]|abstract[125]	new[124]|new[125]	_	_
13-29	2220-2224	main	abstract[124]|abstract[125]	new[124]|new[125]	_	_
13-30	2225-2236	significant	abstract[124]|abstract[125]	new[124]|new[125]	_	_
13-31	2237-2249	determinants	abstract[124]|abstract[125]	new[124]|new[125]	_	_
13-32	2250-2253	for	abstract[124]|abstract[125]	new[124]|new[125]	_	_
13-33	2254-2258	this	abstract[124]|abstract[125]|abstract[126]	new[124]|new[125]|new[126]	_	_
13-34	2259-2270	improvement	abstract[124]|abstract[125]|abstract[126]	new[124]|new[125]|new[126]	_	_
13-35	2271-2272	.	_	_	_	_

#Text=Nevertheless , despite the available evidence , the molecular mechanisms underlying the cardiovascular protection attributable to iSGLT2 treatment are still unknown , though amelioration of oxidative stress has been hypothesized to be a potential contributor .
14-1	2273-2285	Nevertheless	_	_	_	_
14-2	2286-2287	,	_	_	_	_
14-3	2288-2295	despite	_	_	_	_
14-4	2296-2299	the	abstract[127]	new[127]	_	_
14-5	2300-2309	available	abstract[127]	new[127]	_	_
14-6	2310-2318	evidence	abstract[127]	new[127]	_	_
14-7	2319-2320	,	_	_	_	_
14-8	2321-2324	the	abstract[128]	new[128]	_	_
14-9	2325-2334	molecular	abstract[128]	new[128]	_	_
14-10	2335-2345	mechanisms	abstract[128]	new[128]	_	_
14-11	2346-2356	underlying	_	_	_	_
14-12	2357-2360	the	abstract[130]	giv[130]	coref	15-22[145_130]
14-13	2361-2375	cardiovascular	abstract|abstract[130]	giv|giv[130]	_	_
14-14	2376-2386	protection	abstract[130]	giv[130]	_	_
14-15	2387-2399	attributable	_	_	_	_
14-16	2400-2402	to	_	_	_	_
14-17	2403-2409	iSGLT2	object|abstract[132]	giv|giv[132]	coref|coref|coref|coref	18-14[176_0]|19-8[186_132]|18-14[176_0]|19-8[186_132]
14-18	2410-2419	treatment	abstract[132]	giv[132]	_	_
14-19	2420-2423	are	_	_	_	_
14-20	2424-2429	still	_	_	_	_
14-21	2430-2437	unknown	_	_	_	_
14-22	2438-2439	,	_	_	_	_
14-23	2440-2446	though	_	_	_	_
14-24	2447-2459	amelioration	abstract[133]	new[133]	_	_
14-25	2460-2462	of	abstract[133]	new[133]	_	_
14-26	2463-2472	oxidative	abstract[133]|abstract[134]	new[133]|giv[134]	coref	16-1[149_134]
14-27	2473-2479	stress	abstract[133]|abstract[134]	new[133]|giv[134]	_	_
14-28	2480-2483	has	_	_	_	_
14-29	2484-2488	been	_	_	_	_
14-30	2489-2501	hypothesized	_	_	_	_
14-31	2502-2504	to	_	_	_	_
14-32	2505-2507	be	_	_	_	_
14-33	2508-2509	a	abstract[135]	new[135]	_	_
14-34	2510-2519	potential	abstract[135]	new[135]	_	_
14-35	2520-2531	contributor	abstract[135]	new[135]	_	_
14-36	2532-2533	.	_	_	_	_

#Text=Because cardiac tissue possesses low antioxidant defenses , increasing the expression or activity of antioxidant enzymes could be a mechanism of cardiac protection under high risk situations such as T2D .
15-1	2534-2541	Because	_	_	_	_
15-2	2542-2549	cardiac	object[136]	new[136]	coref	16-35[0_136]
15-3	2550-2556	tissue	object[136]	new[136]	_	_
15-4	2557-2566	possesses	_	_	_	_
15-5	2567-2570	low	abstract[138]	giv[138]	_	_
15-6	2571-2582	antioxidant	abstract|abstract[138]	giv|giv[138]	coref	15-15
15-7	2583-2591	defenses	abstract[138]	giv[138]	_	_
15-8	2592-2593	,	_	_	_	_
15-9	2594-2604	increasing	_	_	_	_
15-10	2605-2608	the	abstract[139]	new[139]	coref	20-5[197_139]
15-11	2609-2619	expression	abstract[139]	new[139]	_	_
15-12	2620-2622	or	_	_	_	_
15-13	2623-2631	activity	abstract[140]	new[140]	coref	23-22[224_140]
15-14	2632-2634	of	abstract[140]	new[140]	_	_
15-15	2635-2646	antioxidant	abstract[140]|abstract|substance[142]	new[140]|giv|new[142]	coref|coref|coref|coref	20-9|20-8[199_142]|20-9|20-8[199_142]
15-16	2647-2654	enzymes	abstract[140]|substance[142]	new[140]|new[142]	_	_
15-17	2655-2660	could	_	_	_	_
15-18	2661-2663	be	_	_	_	_
15-19	2664-2665	a	abstract[143]	new[143]	_	_
15-20	2666-2675	mechanism	abstract[143]	new[143]	_	_
15-21	2676-2678	of	abstract[143]	new[143]	_	_
15-22	2679-2686	cardiac	abstract[143]|person|abstract[145]	new[143]|new|giv[145]	_	_
15-23	2687-2697	protection	abstract[143]|abstract[145]	new[143]|giv[145]	_	_
15-24	2698-2703	under	abstract[143]|abstract[145]	new[143]|giv[145]	_	_
15-25	2704-2708	high	abstract[143]|abstract[145]|abstract[147]	new[143]|giv[145]|new[147]	_	_
15-26	2709-2713	risk	abstract[143]|abstract[145]|abstract|abstract[147]	new[143]|giv[145]|new|new[147]	_	_
15-27	2714-2724	situations	abstract[143]|abstract[145]|abstract[147]	new[143]|giv[145]|new[147]	_	_
15-28	2725-2729	such	abstract[143]|abstract[145]|abstract[147]	new[143]|giv[145]|new[147]	_	_
15-29	2730-2732	as	abstract[143]|abstract[145]|abstract[147]	new[143]|giv[145]|new[147]	_	_
15-30	2733-2736	T2D	abstract[143]|abstract[145]|abstract[147]|abstract	new[143]|giv[145]|new[147]|giv	coref	19-5
15-31	2737-2738	.	_	_	_	_

#Text=Oxidative stress occurs when the production of pro-oxidant species overcomes the intrinsic antioxidant defense system of the cell , thus triggering damage to lipids , proteins and DNA , and eventually compromising cellular and tissue function .
16-1	2739-2748	Oxidative	abstract[149]	giv[149]	coref	17-14[0_149]
16-2	2749-2755	stress	abstract[149]	giv[149]	_	_
16-3	2756-2762	occurs	_	_	_	_
16-4	2763-2767	when	_	_	_	_
16-5	2768-2771	the	abstract[150]	giv[150]	coref	19-14[190_150]
16-6	2772-2782	production	abstract[150]	giv[150]	_	_
16-7	2783-2785	of	abstract[150]	giv[150]	_	_
16-8	2786-2797	pro-oxidant	abstract[150]|plant[151]	giv[150]|new[151]	_	_
16-9	2798-2805	species	abstract[150]|plant[151]	giv[150]|new[151]	_	_
16-10	2806-2815	overcomes	_	_	_	_
16-11	2816-2819	the	abstract[154]	giv[154]	_	_
16-12	2820-2829	intrinsic	abstract[154]	giv[154]	_	_
16-13	2830-2841	antioxidant	person|abstract[154]	new|giv[154]	coref	23-18
16-14	2842-2849	defense	abstract|abstract[154]	new|giv[154]	_	_
16-15	2850-2856	system	abstract[154]	giv[154]	_	_
16-16	2857-2859	of	abstract[154]	giv[154]	_	_
16-17	2860-2863	the	abstract[154]|object[155]	giv[154]|new[155]	_	_
16-18	2864-2868	cell	abstract[154]|object[155]	giv[154]|new[155]	_	_
16-19	2869-2870	,	_	_	_	_
16-20	2871-2875	thus	_	_	_	_
16-21	2876-2886	triggering	_	_	_	_
16-22	2887-2893	damage	abstract[156]	new[156]	_	_
16-23	2894-2896	to	abstract[156]	new[156]	_	_
16-24	2897-2903	lipids	abstract[156]|substance	new[156]|new	_	_
16-25	2904-2905	,	abstract[156]	new[156]	_	_
16-26	2906-2914	proteins	abstract[156]|substance	new[156]|new	_	_
16-27	2915-2918	and	abstract[156]	new[156]	_	_
16-28	2919-2922	DNA	abstract[156]|substance	new[156]|new	_	_
16-29	2923-2924	,	_	_	_	_
16-30	2925-2928	and	_	_	_	_
16-31	2929-2939	eventually	_	_	_	_
16-32	2940-2952	compromising	_	_	_	_
16-33	2953-2961	cellular	abstract	new	_	_
16-34	2962-2965	and	_	_	_	_
16-35	2966-2972	tissue	object|abstract[162]	giv|new[162]	coref|coref	24-24[238_0]|24-24[238_0]
16-36	2973-2981	function	abstract[162]	new[162]	_	_
16-37	2982-2983	.	_	_	_	_

#Text=Exploring the role of SGLT2 inhibition in the prevention or reduction of oxidative stress conditions has been the subject of several studies over the last decade .
17-1	2984-2993	Exploring	_	_	_	_
17-2	2994-2997	the	abstract[163]	new[163]	_	_
17-3	2998-3002	role	abstract[163]	new[163]	_	_
17-4	3003-3005	of	abstract[163]	new[163]	_	_
17-5	3006-3011	SGLT2	abstract[163]|abstract|abstract[165]	new[163]|new|new[165]	_	_
17-6	3012-3022	inhibition	abstract[163]|abstract[165]	new[163]|new[165]	_	_
17-7	3023-3025	in	abstract[163]|abstract[165]	new[163]|new[165]	_	_
17-8	3026-3029	the	abstract[163]|abstract[165]|abstract[166]	new[163]|new[165]|new[166]	_	_
17-9	3030-3040	prevention	abstract[163]|abstract[165]|abstract[166]	new[163]|new[165]|new[166]	_	_
17-10	3041-3043	or	abstract[163]|abstract[165]	new[163]|new[165]	_	_
17-11	3044-3053	reduction	abstract[163]|abstract[165]|abstract[167]	new[163]|new[165]|new[167]	coref	19-11[187_167]
17-12	3054-3056	of	abstract[163]|abstract[165]|abstract[167]	new[163]|new[165]|new[167]	_	_
17-13	3057-3066	oxidative	abstract[163]|abstract[165]|abstract[167]|abstract[169]	new[163]|new[165]|new[167]|new[169]	_	_
17-14	3067-3073	stress	abstract[163]|abstract[165]|abstract[167]|abstract|abstract[169]	new[163]|new[165]|new[167]|giv|new[169]	coref	18-16[178_0]
17-15	3074-3084	conditions	abstract[163]|abstract[165]|abstract[167]|abstract[169]	new[163]|new[165]|new[167]|new[169]	_	_
17-16	3085-3088	has	_	_	_	_
17-17	3089-3093	been	_	_	_	_
17-18	3094-3097	the	abstract[170]	new[170]	_	_
17-19	3098-3105	subject	abstract[170]	new[170]	_	_
17-20	3106-3108	of	abstract[170]	new[170]	_	_
17-21	3109-3116	several	abstract[170]|abstract[171]	new[170]|giv[171]	coref	18-6[174_171]
17-22	3117-3124	studies	abstract[170]|abstract[171]	new[170]|giv[171]	_	_
17-23	3125-3129	over	abstract[170]|abstract[171]	new[170]|giv[171]	_	_
17-24	3130-3133	the	abstract[170]|abstract[171]|time[172]	new[170]|giv[171]|new[172]	_	_
17-25	3134-3138	last	abstract[170]|abstract[171]|time[172]	new[170]|giv[171]|new[172]	_	_
17-26	3139-3145	decade	abstract[170]|abstract[171]|time[172]	new[170]|giv[171]|new[172]	_	_
17-27	3146-3147	.	_	_	_	_

#Text=However , to date , most of the studies evaluating the effect of iSGLT2 on oxidative stress have been performed in animal models .
18-1	3148-3155	However	_	_	_	_
18-2	3156-3157	,	_	_	_	_
18-3	3158-3160	to	_	_	_	_
18-4	3161-3165	date	time	new	_	_
18-5	3166-3167	,	_	_	_	_
18-6	3168-3172	most	abstract[174]	giv[174]	coref	23-7[218_174]
18-7	3173-3175	of	abstract[174]	giv[174]	_	_
18-8	3176-3179	the	abstract[174]	giv[174]	_	_
18-9	3180-3187	studies	abstract[174]	giv[174]	_	_
18-10	3188-3198	evaluating	_	_	_	_
18-11	3199-3202	the	abstract[175]	giv[175]	_	_
18-12	3203-3209	effect	abstract[175]	giv[175]	_	_
18-13	3210-3212	of	abstract[175]	giv[175]	_	_
18-14	3213-3219	iSGLT2	abstract[175]|object[176]	giv[175]|giv[176]	coref	19-8[0_176]
18-15	3220-3222	on	abstract[175]|object[176]	giv[175]|giv[176]	_	_
18-16	3223-3232	oxidative	abstract[175]|object[176]|abstract|abstract[178]	giv[175]|giv[176]|giv|giv[178]	_	_
18-17	3233-3239	stress	abstract[175]|object[176]|abstract[178]	giv[175]|giv[176]|giv[178]	_	_
18-18	3240-3244	have	_	_	_	_
18-19	3245-3249	been	_	_	_	_
18-20	3250-3259	performed	_	_	_	_
18-21	3260-3262	in	_	_	_	_
18-22	3263-3269	animal	person|abstract[180]	new|new[180]	coref|coref	23-10[219_180]|23-10[219_180]
18-23	3270-3276	models	abstract[180]	new[180]	_	_
18-24	3277-3278	.	_	_	_	_

#Text=Our data demonstrate that T2D patients receiving iSGLT2 treatment undergo a reduction in mitochondrial superoxide production in parallel to an increase in glutathione content , and markedly so after 24 weeks of treatment .
19-1	3279-3282	Our	person|abstract[182]	giv|new[182]	ana|ana	23-1|23-1
19-2	3283-3287	data	abstract[182]	new[182]	_	_
19-3	3288-3299	demonstrate	_	_	_	_
19-4	3300-3304	that	_	_	_	_
19-5	3305-3308	T2D	abstract|person[184]	giv|giv[184]	coref|coref	23-13|23-13
19-6	3309-3317	patients	person[184]	giv[184]	_	_
19-7	3318-3327	receiving	_	_	_	_
19-8	3328-3334	iSGLT2	abstract|abstract[186]	giv|giv[186]	coref|coref|coref|coref	19-33[0_186]|24-3|19-33[0_186]|24-3
19-9	3335-3344	treatment	abstract[186]	giv[186]	_	_
19-10	3345-3352	undergo	_	_	_	_
19-11	3353-3354	a	abstract[187]	giv[187]	_	_
19-12	3355-3364	reduction	abstract[187]	giv[187]	_	_
19-13	3365-3367	in	abstract[187]	giv[187]	_	_
19-14	3368-3381	mitochondrial	abstract[187]|object|abstract[190]	giv[187]|giv|giv[190]	ana|ana	20-1[0_190]|20-1[0_190]
19-15	3382-3392	superoxide	abstract[187]|substance|abstract[190]	giv[187]|giv|giv[190]	coref	24-18
19-16	3393-3403	production	abstract[187]|abstract[190]	giv[187]|giv[190]	_	_
19-17	3404-3406	in	abstract[187]|abstract[190]	giv[187]|giv[190]	_	_
19-18	3407-3415	parallel	abstract[187]|abstract[190]	giv[187]|giv[190]	_	_
19-19	3416-3418	to	_	_	_	_
19-20	3419-3421	an	event[191]	new[191]	_	_
19-21	3422-3430	increase	event[191]	new[191]	_	_
19-22	3431-3433	in	event[191]	new[191]	_	_
19-23	3434-3445	glutathione	event[191]|substance|abstract[193]	new[191]|new|new[193]	coref|coref	21-6[206_193]|21-6[206_193]
19-24	3446-3453	content	event[191]|abstract[193]	new[191]|new[193]	_	_
19-25	3454-3455	,	_	_	_	_
19-26	3456-3459	and	_	_	_	_
19-27	3460-3468	markedly	time[194]	new[194]	_	_
19-28	3469-3471	so	time[194]	new[194]	_	_
19-29	3472-3477	after	time[194]	new[194]	_	_
19-30	3478-3480	24	time[194]	new[194]	_	_
19-31	3481-3486	weeks	time[194]	new[194]	_	_
19-32	3487-3489	of	time[194]	new[194]	_	_
19-33	3490-3499	treatment	time[194]|abstract	new[194]|giv	coref	21-13[208_0]
19-34	3500-3501	.	_	_	_	_

#Text=This is accompanied by increased expression of the antioxidant enzymes GSR and CAT .
20-1	3502-3506	This	abstract	giv	_	_
20-2	3507-3509	is	_	_	_	_
20-3	3510-3521	accompanied	_	_	_	_
20-4	3522-3524	by	_	_	_	_
20-5	3525-3534	increased	abstract[197]	giv[197]	coref	24-13[232_197]
20-6	3535-3545	expression	abstract[197]	giv[197]	_	_
20-7	3546-3548	of	abstract[197]	giv[197]	_	_
20-8	3549-3552	the	abstract[197]|substance[199]	giv[197]|giv[199]	_	_
20-9	3553-3564	antioxidant	abstract[197]|abstract|substance[199]	giv[197]|giv|giv[199]	_	_
20-10	3565-3572	enzymes	abstract[197]|substance[199]	giv[197]|giv[199]	_	_
20-11	3573-3576	GSR	abstract[197]|substance[199]|abstract	giv[197]|giv[199]|new	_	_
20-12	3577-3580	and	abstract[197]|substance[199]	giv[197]|giv[199]	_	_
20-13	3581-3584	CAT	abstract[197]|substance[199]|object	giv[197]|giv[199]|new	coref	24-21
20-14	3585-3586	.	_	_	_	_

#Text=However , no changes in plasma protein carbonyl content were observed with empagliflozin treatment at these time-points .
21-1	3587-3594	However	_	_	_	_
21-2	3595-3596	,	_	_	_	_
21-3	3597-3599	no	abstract[202]	giv[202]	_	_
21-4	3600-3607	changes	abstract[202]	giv[202]	_	_
21-5	3608-3610	in	abstract[202]	giv[202]	_	_
21-6	3611-3617	plasma	abstract[202]|object|substance[204]|abstract[206]	giv[202]|giv|new[204]|giv[206]	coref|coref|coref	23-18[223_206]|23-18[223_206]|23-18[223_206]
21-7	3618-3625	protein	abstract[202]|substance[204]|abstract[206]	giv[202]|new[204]|giv[206]	_	_
21-8	3626-3634	carbonyl	abstract[202]|abstract|abstract[206]	giv[202]|new|giv[206]	_	_
21-9	3635-3642	content	abstract[202]|abstract[206]	giv[202]|giv[206]	_	_
21-10	3643-3647	were	_	_	_	_
21-11	3648-3656	observed	_	_	_	_
21-12	3657-3661	with	_	_	_	_
21-13	3662-3675	empagliflozin	substance|abstract[208]	giv|giv[208]	ana|coref|ana|coref	22-2[0_208]|22-15|22-2[0_208]|22-15
21-14	3676-3685	treatment	abstract[208]	giv[208]	_	_
21-15	3686-3688	at	abstract[208]	giv[208]	_	_
21-16	3689-3694	these	abstract[208]|time[209]	giv[208]|new[209]	_	_
21-17	3695-3706	time-points	abstract[208]|time[209]	giv[208]|new[209]	_	_
21-18	3707-3708	.	_	_	_	_

#Text=Whether this could be due to the small sample size or would require long-term empagliflozin treatment needs to be addressed in future research .
22-1	3709-3716	Whether	_	_	_	_
22-2	3717-3721	this	abstract	giv	coref	22-14[214_0]
22-3	3722-3727	could	_	_	_	_
22-4	3728-3730	be	_	_	_	_
22-5	3731-3734	due	_	_	_	_
22-6	3735-3737	to	_	_	_	_
22-7	3738-3741	the	quantity[212]	new[212]	_	_
22-8	3742-3747	small	quantity[212]	new[212]	_	_
22-9	3748-3754	sample	object|quantity[212]	new|new[212]	_	_
22-10	3755-3759	size	quantity[212]	new[212]	_	_
22-11	3760-3762	or	_	_	_	_
22-12	3763-3768	would	_	_	_	_
22-13	3769-3776	require	_	_	_	_
22-14	3777-3786	long-term	abstract[214]	giv[214]	coref	24-3[228_214]
22-15	3787-3800	empagliflozin	substance|abstract[214]	giv|giv[214]	_	_
22-16	3801-3810	treatment	abstract[214]	giv[214]	_	_
22-17	3811-3816	needs	_	_	_	_
22-18	3817-3819	to	_	_	_	_
22-19	3820-3822	be	_	_	_	_
22-20	3823-3832	addressed	_	_	_	_
22-21	3833-3835	in	_	_	_	_
22-22	3836-3842	future	abstract[215]	new[215]	_	_
22-23	3843-3851	research	abstract[215]	new[215]	_	_
22-24	3852-3853	.	_	_	_	_

#Text=Our findings are in accordance with previous studies in rat models of T2D , in which increased antioxidant enzyme content and activity in renal tissues has been reported .
23-1	3854-3857	Our	person|abstract[217]	giv|new[217]	_	_
23-2	3858-3866	findings	abstract[217]	new[217]	_	_
23-3	3867-3870	are	_	_	_	_
23-4	3871-3873	in	_	_	_	_
23-5	3874-3884	accordance	_	_	_	_
23-6	3885-3889	with	_	_	_	_
23-7	3890-3898	previous	abstract[218]	giv[218]	_	_
23-8	3899-3906	studies	abstract[218]	giv[218]	_	_
23-9	3907-3909	in	abstract[218]	giv[218]	_	_
23-10	3910-3913	rat	abstract[218]|abstract[219]	giv[218]|giv[219]	_	_
23-11	3914-3920	models	abstract[218]|abstract[219]	giv[218]|giv[219]	_	_
23-12	3921-3923	of	abstract[218]|abstract[219]	giv[218]|giv[219]	_	_
23-13	3924-3927	T2D	abstract[218]|abstract[219]|abstract	giv[218]|giv[219]|giv	_	_
23-14	3928-3929	,	_	_	_	_
23-15	3930-3932	in	_	_	_	_
23-16	3933-3938	which	_	_	_	_
23-17	3939-3948	increased	_	_	_	_
23-18	3949-3960	antioxidant	person|abstract[223]	giv|giv[223]	coref|coref	24-13|24-13
23-19	3961-3967	enzyme	substance|abstract[223]	new|giv[223]	_	_
23-20	3968-3975	content	abstract[223]	giv[223]	_	_
23-21	3976-3979	and	_	_	_	_
23-22	3980-3988	activity	abstract[224]	giv[224]	_	_
23-23	3989-3991	in	abstract[224]	giv[224]	_	_
23-24	3992-3997	renal	abstract[224]|abstract|object[226]	giv[224]|new|new[226]	_	_
23-25	3998-4005	tissues	abstract[224]|object[226]	giv[224]|new[226]	_	_
23-26	4006-4009	has	_	_	_	_
23-27	4010-4014	been	_	_	_	_
23-28	4015-4023	reported	_	_	_	_
23-29	4024-4025	.	_	_	_	_

#Text=Furthermore , iSGLT2 treatment in diabetic mice has been shown to induce antioxidant gene expression ( manganese-dependent superoxide dismutase and CAT ) in adipose tissue and muscle .
24-1	4026-4037	Furthermore	_	_	_	_
24-2	4038-4039	,	_	_	_	_
24-3	4040-4046	iSGLT2	abstract|abstract[228]	giv|giv[228]	_	_
24-4	4047-4056	treatment	abstract[228]	giv[228]	_	_
24-5	4057-4059	in	abstract[228]	giv[228]	_	_
24-6	4060-4068	diabetic	abstract[228]|animal[229]	giv[228]|new[229]	_	_
24-7	4069-4073	mice	abstract[228]|animal[229]	giv[228]|new[229]	_	_
24-8	4074-4077	has	_	_	_	_
24-9	4078-4082	been	_	_	_	_
24-10	4083-4088	shown	_	_	_	_
24-11	4089-4091	to	_	_	_	_
24-12	4092-4098	induce	_	_	_	_
24-13	4099-4110	antioxidant	person|abstract[232]	giv|giv[232]	appos|appos	24-17[235_232]|24-17[235_232]
24-14	4111-4115	gene	abstract|abstract[232]	new|giv[232]	_	_
24-15	4116-4126	expression	abstract[232]	giv[232]	_	_
24-16	4127-4128	(	_	_	_	_
24-17	4129-4148	manganese-dependent	substance[234]|abstract[235]	new[234]|giv[235]	_	_
24-18	4149-4159	superoxide	substance|substance[234]|abstract[235]	giv|new[234]|giv[235]	_	_
24-19	4160-4169	dismutase	substance[234]|abstract[235]	new[234]|giv[235]	_	_
24-20	4170-4173	and	abstract[235]	giv[235]	_	_
24-21	4174-4177	CAT	abstract[235]|object	giv[235]|giv	_	_
24-22	4178-4179	)	_	_	_	_
24-23	4180-4182	in	_	_	_	_
24-24	4183-4190	adipose	abstract|object[238]	new|giv[238]	_	_
24-25	4191-4197	tissue	object[238]	giv[238]	_	_
24-26	4198-4201	and	_	_	_	_
24-27	4202-4208	muscle	object	new	_	_
24-28	4209-4210	.	_	_	_	_
